KR890008104A - 디아릴스티릴퀴놀린 이산 - Google Patents

디아릴스티릴퀴놀린 이산 Download PDF

Info

Publication number
KR890008104A
KR890008104A KR1019880015470A KR880015470A KR890008104A KR 890008104 A KR890008104 A KR 890008104A KR 1019880015470 A KR1019880015470 A KR 1019880015470A KR 880015470 A KR880015470 A KR 880015470A KR 890008104 A KR890008104 A KR 890008104A
Authority
KR
South Korea
Prior art keywords
phenyl
benzoic acid
chloro
thio
quinolinyl
Prior art date
Application number
KR1019880015470A
Other languages
English (en)
Inventor
엔.영 로버트
잠보니 로버트
이브 고티에르 자크
엘.벨리 미셀
Original Assignee
쟝 씨.브렐
머크 프로스트 캐나다, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쟝 씨.브렐, 머크 프로스트 캐나다, 인코포레이티드 filed Critical 쟝 씨.브렐
Publication of KR890008104A publication Critical patent/KR890008104A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

내용 없음

Description

디아릴스티릴퀴놀린 이산
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 일반식 (I)의 화합물 및 약제학적으로 허용되는 이의 염
    상기식에서, R¹은 H, 할로겐, C1-8알킬, C2-8알케닐, C2-8알키닐, -CF₃, -SR², -S(O)R², -S(O)₂R², NR³R³, OR³,-COOR³, -(C=O)R³, -C(OH)R³R³, -CN, NO₂, -N₃,치환되거나 비치환된 페닐, 치환되거나 비치환된 벤질, 치환되거나 비치환된 2-펜에틸 또는 치환되거나 비치환된 피리딜이고, R²는 C1-8알킬, C2-8알케닐, C2-8알키닐, -CF₃, 치환되거나 비치환된 페닐, 치환되거나 비치환된 벤질, 또는 치환되거나 비치환된 2-펜에틸이며, R³은 H 또는 R²이고, R⁴는 H, 할로겐, -NO₂, -CN, -OR³, -SR³, NR³R³, 또는 C1-C8알킬이며, CR³R⁴는 천연 아미노산의 라디칼일 수 있고, R5는 H, 할로겐, -NO₂, -N₃, -CN, -SR², -NR³R³, -OR³, C1-C8알킬 또는 -(C=O)R³이며 R6은 -(CH2)5-C(R7R7)-(CH2)5-R3또는 -CH2CONR12R12이고, R7은 H 또는 C₁-C₄알킬이며, R8은 A)핵탄소원자 3개 내지 12개 및 N, S 및 0중에서 선택된 핵헤테로원자 1 또는 2개로 구성되고 헤테로사이클릭 라디칼의 각 환이 5 또는 6개의 원자로 형성된 모노사이클릭 또는 비사이클릭 헤테로사이클릭 라디킬이거나, B) 라디칼 W-R9이고 R9는 21개이하의 탄소원자를 가지며, (1)탄화수소 라디칼 또는 (2) 환내에 최대 1개의 헤테로원자를 갖는 유기 아사이클릭 또는 모노사이클릭 카복실산의 아실 라디칼이며, R10은 -SR11, -OR12또는 -NR12R12이고, R11은 C1-C6알킬, -(C=O)R14, 비치환된 페닐 또는 비치환된 벤질이며, R12는 H 또는 R11이거나, 동일한 N에 결합된 두 개의 R12그룹은 O,S 및 N중에서 선택된 2개 이하의 헤테로원자를 갖는 5 또는 6원환을 형성할 수 있고, R13은 C1-C8알킬, C2-C8알케닐, C2-C8알키닐, -CF₃, 또는 비치횐된 페닐, 벤질 또는 2-펜에틸이며, R14는 H 또는 R13이고 , R15는 R³또는 할로겐이며, R16은 H, C₁-C₄알킬 또는 OH이고 m 및 m′는 독립적으로 0내지 8이며, n 및 n′는 독립적으로 0 또는 1 이지만 둘다 0은 아니고 p 및 p′는 독립적으로 0 내자 8이며 m+n+p는 X²가CR³R16일 경우 0내지 10이며, m′+n′+p′는 X³가 O,S,S,(O) 또는 S(O)₂일 경우 1내지 10이고, m′+n′+p′는 X³가 CR3R16일 경우 0 또는 10이며, r은 Z′이 HET (-R³, -R5)일 경우 0 또는 1 이고 r은 Z¹이 -CONR³일 경우 1 이며, r′은 Z²이 HET(-R², -R5)일 경우 0 또는 1이고 r′은 Z₂이 -CONR³일 경우 1이며, S는 0 내지 3이고, Q¹ 및 Q²는 독립적으로 -COOR³, 테트라졸, -COOR6, -CONHS(O)2R13, CN, -CONR12R12, -CHO, -CH₂OH, -COCH₂OH, 또는 -NHS(O)2R13이거나, Q¹또는 Q²가 COOH 이고 R⁴가 -OH, -SH, 또는 -NHR³ 이면 Q¹또는 Q² 및 R⁴은 이들이 결합된 탄소와 함께 물을 방출시키면서 헤테로사이클릭 환을 형성할 수 있으며, W는 O, S 또는 NR³이고 X¹은 O,S,-S(O)₂-, -NR³또는 -CR³R³-이며, X² 및 X³는 독립적으로 O, S, S(O), S(O)₂ 또는 CR3R16이고, Y는 -CR³=CR³-, -C = C-, -CR³R³-X¹, -X¹-CR³R³, -CR³R³-X¹-CR³R³-, C = 0,, O, S, 또는 NR³이며 Z¹ 및 Z²는 독립적으로 -CONR³-또는 -HET(-R3-R5)-이고, 단, 이들중 적어도 하나는 -HET(-R3-R5)-이며
  2. 제 1 항에 있어서 치환체가 하기와 같은 일반식(I′)의 화합물
  3. 제 2 항에 있어서, 2-(3-(3-(2-(7-클로로퀴놀린-2-일)에테닐)페닐)-3-(2-카복시 에틸티오)프로필)벤조산, 이나트륨염 : 2-(3-(3-(2-(7-클로로퀴놀린-2-일)에테닐)페닐)-3-(2-디메틸카바모일)에틸티오)프로필)벤조산, 나트륨염: 3-(3-(2-(7-클로로퀴놀린-2-일)에틸)페닐)-3-(2-디메틸카보모일)에틸티오)메틸)벤조산 나트륨염: 5-(3-(2-(7-클로로퀴놀린-2-일)에테닐)페닐)-(2-디메틸카바모일)에틸티오)메틸)티오펜-2-카복실산 : 3-(3-(2-(7-클로로퀴놀린-2-일)에테닐)페닐)-(2-디메틸카바모일)에틸티오)메틸)벤조산 : 4-((3-(2-(7-클로로퀴놀린-2-일)에테닐)페닐)-3-(2-디메틸카바모일)에틸티오)프로필)벤조산 : 3-((2-카복시에틸티오)(3-(2-(7-클로로놀린-2-일)-에테닐)페닐)메틸)벤조산 : 6-(3-카복시에틸티오)-6-(3-(2-(7-클로로놀린-2-일)-에테닐)페닐)-3-메틸헥사노산 : (3-((3-(7-클로로퀴놀린-2-일메틸)옥시)페닐)(2-디메틸카바모일)에틸티오)프로필)벤조산,나트륨염 : 3-(3-카복시페틸티오)(3-(2-(7-클로로퀴놀린 -2-일)에테닐)페닐)메틸)벤조산 : (3-(3-(7-클로로퀴놀린-2-일테닐)옥시)페닐)(2-(t-부틸카바모일)에틸티오)메틸)벤조산, 나트륨염 : (5-(3-(7-클로로퀴놀린-2-퀴놀리닐)메톡시)페닐)(3-디메틸아미노-3-옥소프로필)티오)메틸)-3-피리딘카복실산, 나트륨염: 3,3′-(((3-((7-클로로-2-퀴놀리닐)메톡시)페닐)-메틸렌)비스(벤조산), 이나트륨염 : 3-(((4-카복시페닐)티오) (3-(2-(7-클로로-2-퀴노리닐)에테닐)페닐)벤조산, 이나트륨염 : 3-3(((4-카복시페닐)티오)(3-(2-(7-클로로-2-퀴노리??닐)에테닐)페닐)벤조산, 이나트륨염: 3-((3-(2-(7-클로로-2-퀴노리닐)에테닐)페닐)((4-(디메틸아미노 카보닐)페닐)티오)메틸)벤조산, 나트륨염 : 3-(2-(2-카복시에틸)티오)-2-(3-(7-클로로-2-퀴놀리닐)메톡시)페닐)에틸)벤조산 : 3-(1-(3-(2-(7-클로로-2-퀴노리닐)에테닐)페닐)-1-((2-카복시-4-피리디닐)티오)메틸)벤조산 : 3-(1-((2-키복시페닐)치오)-1-(3-(2-(7-클로로-2-퀴놀리닐)메톡시)페닐)메틸)벤조산, 이나트륨염 : 2-(3-(3-(7-클로로-2-퀴놀리닐)메톡시)페닐)-3-((2-카복시에틸)티오)프로필)벤조산, 나트륨염 : 2,2′(((3-((7-클로로-2-퀴놀리닐)메톡시)페닐)-메틸렌)비스(티오)비스(벤조산), 이나트륨염 :2-클로로-5-(3-((7-클로로-2-퀴놀리닐)메톡시)페닐)-((3-디메틸아미노-3-옥소프로필)티오)메틸)벤조산, 나트륨염 : 2,2′(((3-((7-클로로-2-퀴놀리닐)메톡시)페닐)-메틸렌)비스(티오메틸)비스(벤조산) 이나트륨염 : 2((((3-(7-3-디메틸아미노-3-옥소프로필)티오)메틸)벤조산 : 3-((3-(2-(7-클로로-2-퀴놀리닐)메톡시)페닐)-((3-(3-(2-메틸-2-프로필)아미노)3-옥소프리필)티오)메틸)벤조산, 나트륨염 :2-((3-(3-(2-(7-클로로-2-퀴놀리닐)에틸)페닐)-3-((3-디메틸아미노)-3-오소프리필)티오)프로필)벤조산 : 2-((3-((7-클로로-2-퀴놀리닐)메톡시)페닐)((3-디메틸아미노-3-옥소프로필)티오)메틸)벤조산 : 2-((3-(7-클로로-2-퀴놀리닐)메톡시)페닐)((3-디메틸아미노-3-옥소프로필)티오)메틸)벤조산 : 2-((3-(3-(7-클로로-2-퀴놀리닐)메톡시)페닐)-3-((3-옥소-3-(1-(트리시클로 [3,3,1,13,7]데실)아미노)프로필)-티오)프로필)벤조산, 나트륨염 : N,N-디메틸3-((1-3((7-클로로-2-퀴놀리닐)메톡시)페닐)-3-(2-(1H-테트라졸-5-일)메틸)-페닐)프로필)티오)프로판아미도, 나트륨염: N,N-디메틸3-((1-3((7-클로로-2-퀴놀리닐)메톡시)페닐)-3-(2-(1H-테트라졸-5-일)메틸)-페닐)프로필)티오)프로판아미도, 나트륨염: 2-(3-(3-((7-클로로-2-퀴놀리닐)메톡시)페닐)-3(3-디메틸아미노-3-옥소프로필)티오)프로필)벤젠아세트산,나트륨염: 3-((1-(3-((7-클로로-2퀴놀리닐)메톡시)페닐)-3-(2-디메틸아미노카보닐)페닐)프로필)티오)프로파로나산, 나트륨염: N,N-디메틸3-((1-3((7-클로로-2-퀴놀리닐)메톡시)페닐)-1-(3-(1H-테트라졸-5-일)메틸)-페닐)프로필)티오)프로판아미도, 나트륨염: 또는 3-(((3-카복시페닐)티오)(3-((7-클로로-2-퀴노리닐)-메톡시)페닐)메틸)벤조산, 이나트륨염인 화합물
  4. 제 1 항에 있어서, R¹가 H, 할로겐, C1-C8알킬, -CF₃, -SR², -S(O)R², S(O)₂R², -OR³, 또는-CN이고, R²가 C1-C8알킬 또는 -CF₃이며 R⁴가 H, -OR³, -SR³, NR³R³또는 C1-C8알킬이고, CR³R⁴가 천연 아미노산의 라디칼일 수 있으며, R5가 H, 할로겐, -CN, -SR², -OR³ C1-C8알킬 또는 -(C=0)R³이고 R13가 C1-C8알킬, -CF₃또는 비치환된 페닐, 벤질, 또는 2-펜에틸이여, m 및 m가 독립적으로 0내지 4이고, p 및 p가 독립적으로 0 내지 4이며, m+n+p는 X²가 0또는 10이고, m′+n′+p′는 X³가 0또는 S인 경우 1내지 10이며 Q¹ 및 Q²는 독립적으로 -COOR³, 테트라졸, -COOR6, -CHNHS(O)₂R³, -CONR12, -NHS(O)2R13이거나, Q¹ 및 Q² 가 COOH이고, R⁴가 -OH, -SH또는 -NHR³이면, Q¹ 또는 Q² 및 R⁴는 이들이 결합된 탄소와 함께 물을 방출시키면서 헤테로시클릭환을 형성할 수 있고, W가 O,S 또는 NH이며, X¹가 O, S, -NR³, 또는 -CR³R³-이고 X² 및 X³가 독립적으로 O, S, 또는 SR3R16이며, Y가 -CR³=CR³-X¹-, 또는 X¹-CR³R³-인 화합물 및 약제학적으로 허용되는 이의 염
  5. 제 1 항에 있어서, R¹가 H, 할로겐, C1-C8알킬, -CF₃, -SR², -S(O)R², S(O)₂R², -OR³, 또는-CN이고, R²가 C1-C8알킬 또는 -CF₃이며 R⁴가 H, -OR³, -SR³, NR³R³또는 C1-C8알킬이고, CR³R⁴가 천연 아미조산의 라디칼일 수 있으며, R5가 H, 할로겐, -CN, -SR², -OR³, C1-C8알킬 또는 -(C=0)R³이고 R13가 C1-C8알킬, -CF₃또는 비치횐된 페닐, 벤질, 또는 2-펜에틸이여, m 및 m가 독립적으로 0내지 4이고, p 및 p가 독립적으로 0 내지 4이며, m+n+p는 X²가 0또는 10이고, m′+n′+p′는 X³가 0또는 S인 경우 1내지 10이며 Q¹ 및 Q²는 독립적으로 -COOR³, 테트라졸, 또는 -CONR12R12이고, W가 O 또는 NH이며 X¹가 O, S, -NR³, 또는 -CR³R³-이고 X² 및 X³가 독립적으로 O, S,또는 -CR³R³-이고 Z¹ 및 Z²가 HET(-R3-R5-) 인 화합물 및 약제학적으로 허용되는 이의 염
  6. 일반식(Ia)의 화합물
    상기식에서 R⁴는 H 또는 C1-C8알킬이고, CR³R⁴는 천연 아미노산의 라디칼이 아니며, m은 1 내지 4이고, m′는 0내지 4이며, p′는 0내지 4이고, r′는 0 또는 1이며, Q¹ 및 Q²는 독립적으로 -COOR³, 테트라졸, -CONHS(O)₂R13또는 -CONR12R12이고 X³는 S또는 CR3R16이며 Y는 -CH=CH-또는 CH₂O- 이고 나머지 라디칼의 정의는 제 4 항에서 정의한 바와 같다
  7. 치료유효량의 제 1항에 따른 화합물 및 약학적으로 허용되는 담체를 함유하는 약학적 조성물
  8. 제 7 항에 있어서, 비스테로이드성 소염제, 말초진통제, 사이클로옥시게나제 억제제, 류코트리엔 길항제 , 류코트리엔 생합성 억제제 H₂-수용체 기항제, 항히스타민제, 프로스타글란딘 길항제, 트롬복산 길항제, 트롬복산 합성효소 억제제 및 ACE길항제로 이루어진 그룹 중에서 선택된 유효량의 제 2활성 성분을 추가로 함유하는 약학적 조성물
  9. 제 8 항에 있어서, 제 2 활성 성분이 비스테로이드성 소염제인 약학적 조성물
  10. 제 9 항에 있어서, 제2활성 성분에 대한 제 1 항에 따른 화합물의 중량비가 약 1000: 1 내지 1 : 1000의 범위인 약학적 조성물
  11. 포유동물에게 후효량의 제 1 항에 따른 화합물을 투여함을 특징으로하여, 포유동물에 있어 SRS -A 또는 류코트리엔의 합성, 작용 또는 분비를 방지하는 방법
  12. 제 11항에 있어서, 포유동물이 사람인 방법
  13. 세포보호성 치료를 요하는 포유동물에게 세포보호량의 제 1 항에 따른 화합물을 토여함을 특징으로 하여, 포유동물에 있어 세포보호를 유도하는 방법
  14. 눈의 염증질환의 치료를 요하는 포유동물에게 치료유효량의 제 1 항에 따른 화합물을 투여함을 특징으로하여, 포유동물에 있어 눈의 염증 질환을 치료하는 방법
  15. 제 13 항에 있어서, 포유동물이 사람인 방법
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는것임.
KR1019880015470A 1987-11-25 1988-11-24 디아릴스티릴퀴놀린 이산 KR890008104A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12505087A 1987-11-25 1987-11-25
US125,050 1987-11-25

Publications (1)

Publication Number Publication Date
KR890008104A true KR890008104A (ko) 1989-07-08

Family

ID=22417988

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880015470A KR890008104A (ko) 1987-11-25 1988-11-24 디아릴스티릴퀴놀린 이산

Country Status (10)

Country Link
EP (1) EP0318093A3 (ko)
JP (1) JPH0686433B2 (ko)
KR (1) KR890008104A (ko)
AU (1) AU2589688A (ko)
CA (1) CA1339802C (ko)
DK (1) DK655288A (ko)
IL (1) IL88433A0 (ko)
NZ (1) NZ227036A (ko)
PT (1) PT89075B (ko)
ZA (1) ZA888766B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204358A (en) * 1987-11-25 1993-04-20 Merck Frosst Canada, Inc. Hetaryl styryl quinolines as leukotriene inhibitors
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids
NZ233752A (en) * 1989-05-24 1993-05-26 Merck Frosst Canada Inc Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof
DE3927930A1 (de) * 1989-08-24 1991-02-28 Bayer Ag Cyclisch substituierte (chinolin-2-yl-methoxy)phenyl-essig-saeure-derivate
US5021576A (en) * 1989-10-27 1991-06-04 American Home Products Corporation 2-Anilino phenylacetic acid derivatives
DE69113735T2 (de) * 1990-10-12 1996-06-13 Merck Frosst Canada Inc Hydroxyalkylchinolin Äther Säure als Leukotrien-Antagoniste.
CA2053216C (en) 1990-10-12 2003-04-08 Michel L. Belley Saturated hydroxyalkylquinoline acids as leukotriene antagonists
CA2053209C (en) * 1990-10-12 1998-12-08 Michel L. Belley Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5856322A (en) * 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
US5149703A (en) * 1991-09-06 1992-09-22 Merck Frosst Canada, Inc. Quinoline-substituted chromans and related compounds as leukotriene antagonists
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5506227A (en) * 1992-04-13 1996-04-09 Merck Frosst Canada, Inc. Pyridine-substituted benzyl alcohols as leukotriene antagonists
EP0780127A1 (en) 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
WO1998008820A1 (fr) * 1996-08-26 1998-03-05 Yamanouchi Pharmaceutical Co., Ltd. Composes de benzenesulfone et sels de ces derniers
EP0960096B1 (en) * 1997-01-22 2005-04-06 Aventis Pharmaceuticals Inc. Substituted beta-thiocarboxylic acids
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP4725634B2 (ja) * 2008-11-13 2011-07-13 トヨタ自動車株式会社 無段変速機
JP6038914B2 (ja) 2011-07-26 2016-12-07 スン プハルマ アドバンセド リサーチ カンパニー リミテド キノリン−、キノキサリン、又はベンゾチアゾールベースのシステイニルロイコトリエンアンタゴニスト（ｌｔｃ４）
AU2014225550C1 (en) 2013-03-08 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Potent and selective inhibitors of monoamine transporters; method of making; and use thereof
WO2019094856A1 (en) 2017-11-13 2019-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Atypical inhibitors of monoamine transporters; method of making; and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK282986A (da) * 1985-06-18 1987-02-24 Merck Frosst Canada Inc Substitueret quinolin og farmaceutisk praeparat indeholdende en saadan forbindelse
IE59889B1 (en) * 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
AU612569B2 (en) * 1986-03-13 1991-07-18 Rorer International (Overseas) Inc. Quinolinyl ether or thioether tetrazoles as agents for the treatment of hypersensitive ailments

Also Published As

Publication number Publication date
IL88433A0 (en) 1989-06-30
PT89075A (pt) 1988-12-01
AU2589688A (en) 1989-06-01
DK655288D0 (da) 1988-11-24
JPH0686433B2 (ja) 1994-11-02
NZ227036A (en) 1991-10-25
ZA888766B (en) 1989-08-30
CA1339802C (en) 1998-04-07
DK655288A (da) 1989-08-04
JPH02138259A (ja) 1990-05-28
EP0318093A3 (en) 1990-12-05
EP0318093A2 (en) 1989-05-31
PT89075B (pt) 1993-04-30

Similar Documents

Publication Publication Date Title
KR890008104A (ko) 디아릴스티릴퀴놀린 이산
KR900018035A (ko) 디아릴스티릴퀴놀린 이산
KR910004600A (ko) 류코트리엔의 생합성 억제제로서의 (퀴놀린-2-일메톡시)인돌
EP0045200B1 (en) Benzimidazoles and their pharmaceutical use
RU96112148A (ru) Антагонисты рецепторов эндотелина
US20020143022A1 (en) Method of inhibiting neoplastic cells with indole derivatives
JP2009522292A5 (ko)
US20040019113A1 (en) Phosphate transport inhibitors
JP2007532651A5 (ko)
RU2721844C2 (ru) Ингибиторы urat1
NZ517059A (en) Indole derivatives of benzoic acid which act as peroxisome proliferator activated receptor (PPAR)
EP1371650A4 (en) ACTIVATED RECEPTOR ACTIVATOR BY PEROXYSOME PROLIFIERS
RU2007106969A (ru) Новые пиперидиновые производные в качестве лигандов гистаминового рецептора для лечения депрессии
JP2008533151A5 (ko)
HRP20090641T1 (hr) Pripravci modulatora 5ht2c receptora i postupci uporabe
CA2440037A1 (en) Benzimidazole derivatives for modulating the rage receptor
JP2004537564A5 (ko)
AU6582300A (en) Benzoic acid derivatives for the treatment of diabetes mellitus
HRP20161631T1 (hr) Dihidropirazolni gpr40 modulatori
JP2008508352A5 (ko)
RU97107457A (ru) Производное азола
HRP20192275T1 (hr) Novi spojevi 3,4-dihidro-2h-izokinolin-1-ona i 2,3-dihidro-izoindol-1-ona
JP2004511456A (ja) 糖尿病用薬剤
KR920016423A (ko) 루코트리엔 길항제로서의 퀴놀린-함유 케토산
JP2002520315A5 (ko)

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid